Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May

Related Keywords

United States ,Danielle Spangler ,Abingworth Bioventures ,Gregoryj Flesher ,David Melamed ,Nasdaq ,Drug Administration ,Reneo Pharmaceuticals ,Reneo Pharmaceuticals Inc ,Exchange Commission ,Society For Inherited Metabolic Disorders ,Russo Partners ,Chief Executive Officer ,Fast Track Designation ,Inherited Metabolic Disorders ,Annual Meeting ,Mitochondrial Function ,Skeletal Muscle ,Potential Treatment ,Primary Mitochondrial ,Three Months Ended March ,Private Securities Litigation Reform Act ,Months Ended March ,Gefallene Big Techs ,Reneo ,Pharmaceuticals ,Reports ,First ,Quarter ,023 ,Financial ,Results ,